Is TB-500 Legal in Michigan?

What TB-500 Actually Is

TB-500 is a synthetic version of the active region of thymosin beta-4 (Tβ4), specifically the actin-binding domain peptide Ac-LKKTETQ. Thymosin beta-4 itself is an endogenous 43-amino-acid protein expressed in virtually every human cell type. The synthetic fragment is sold as TB-500, a name that does not appear in any FDA-approved drug database.

Mechanism and Proposed Therapeutic Uses

Tβ4 modulates actin polymerization, supports angiogenesis, and has shown anti-inflammatory properties in preclinical models. A 2010 study published in the Journal of Cardiovascular Pharmacology found that Tβ4 reduced infarct size and improved cardiac function after myocardial injury in rodent models. Researchers have investigated it for wound healing, tendon repair, and cardiac recovery, but no Phase III randomized controlled trial in humans has been completed or published as of mid-2025.

Why the "TB-500" Name Matters Legally

The name TB-500 is a research-market trade name, not a recognized INN (International Nonproprietary Name) or USAN. That distinction matters because FDA approval, compounding legality, and import rules all attach to specific chemical identities. Compounding pharmacies and prescribers must identify the compound by its chemical name (thymosin beta-4 or the specific fragment sequence), not the trade name.

The Federal Legal Framework That Governs TB-500

Understanding whether TB-500 can be legally obtained in Michigan requires understanding federal law first. State rules layer on top of, and cannot contradict, federal baseline requirements.

FDA Approval Status

TB-500 has never received FDA approval under either a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA). The FDA's Drugs@FDA database returns no results for "thymosin beta-4" or "TB-500" as approved finished products. That means any commercial sale of TB-500 as a drug for human use, without a valid exemption such as compounding under FDCA Section 503A or 503B, is unlawful under 21 U.S.C. § 331.

DEA Scheduling

TB-500 is not listed in Schedule I, II, III, IV, or V of the Controlled Substances Act. The DEA Controlled Substances list does not include thymosin beta-4 or any of its synthetic fragments. This means possession of TB-500 is not a federal criminal offense under the CSA, but the absence of scheduling does not make it legal to sell or administer as a drug.

The 503A Bulk Compounding List

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients if the active pharmaceutical ingredient (API) is on FDA's approved 503A Bulks List or meets specific criteria under 21 CFR 216.23. FDA publishes the current 503A Bulks List. As of July 2025, thymosin beta-4 and TB-500 do not appear on that list. FDA has not finalized a positive determination for this compound.

The 503B Outsourcing Facility List

Section 503B covers registered outsourcing facilities that compound in larger quantities without patient-specific prescriptions. The 503B Bulks List similarly does not include thymosin beta-4 as of mid-2025. Outsourcing facilities cannot legally compound TB-500 for human use until and unless FDA makes a positive determination.

Where the Gray Area Actually Comes From

Here is where practitioners and patients often get confused. A substance not on the 503A or 503B bulks lists may still be compounded if FDA has not formally placed it on the "Category 2" (nominated but negative determination) or "Category 1" (currently under review) lists. As of this writing, FDA has not issued a final negative determination specifically for thymosin beta-4 under 503A. That creates a regulatory gap: some compounding pharmacies have interpreted the absence of a formal negative ruling as permissive. The FDA's own guidance, however, states that compounders bear the burden of demonstrating that bulk substances meet the statutory criteria before use. The gray area is real, but it tilts toward caution for any pharmacy operating under close FDA scrutiny.

HealthRX Clinical-Legal Tier Framework for TB-500 (as of July 2025)

| Tier | What it means | TB-500 status | |------|---------------|---------------| | Tier 1: Fully legal, FDA-approved | NDA/ANDA approval, dispensed by any licensed pharmacy | Not applicable | | Tier 2: Compounding-legal | On 503A or 503B Bulks List, requires Rx | Not applicable (not listed) | | Tier 3: Gray-area compounding | Not on list, no final negative determination, some pharmacies compound under legal risk | Current position | | Tier 4: Research chemical only | Sold for in-vitro/non-human use, human administration illegal without IND | Default online purchase | | Tier 5: Prohibited | On DEA schedules or final FDA negative determination | Not applicable |

Michigan State Law and TB-500

Michigan does not have a state statute that specifically names TB-500 or thymosin beta-4. The relevant state-level framework comes from three sources: the Michigan Public Health Code, the Michigan Board of Pharmacy, and the Michigan Department of Licensing and Regulatory Affairs (LARA).

Michigan Board of Pharmacy Rules on Compounding

The Michigan Board of Pharmacy operates under the Michigan Public Health Code (Act 368 of 1978). Michigan-licensed pharmacies that compound sterile preparations, which TB-500 would be given its subcutaneous or intravenous route, must comply with USP Chapter 797 standards and must use APIs from FDA-registered facilities. The Board does not maintain a separate positive list of permitted bulk APIs. Instead, it defers to the federal 503A/503B framework for determining which bulk substances are acceptable. A Michigan pharmacy that compounds TB-500 under a physician prescription is therefore operating in the same gray zone described above at the federal level.

Michigan Medical Practice Act and Physician Prescribing

Under the Michigan Medical Practice Act (MCL 333.17001 et seq.), a licensed Michigan physician may prescribe any drug or compounded preparation within the scope of legitimate medical practice. There is no Michigan law prohibiting a physician from prescribing thymosin beta-4 as a compounded preparation. The physician assumes liability for demonstrating medical necessity, obtaining informed consent, and ensuring the compounding pharmacy is appropriately licensed.

What Michigan Does Not Have

Michigan has not passed a state-level peptide ban analogous to some sports-commission statutes, and it has not issued specific guidance restricting TB-500 beyond the federal baseline. The Michigan Attorney General's office has not issued an opinion specifically targeting this compound. This absence of state-specific restriction is sometimes misread as affirmative legality. It is not. The federal framework still controls.

How to Get TB-500 Legally in Michigan

The only legal pathway for a Michigan resident to obtain TB-500 for personal therapeutic use runs through a licensed physician and a compounding pharmacy willing to operate under the gray-area framework described above.

Step 1: Obtain a Valid Prescription from a Licensed Physician

A physician, physician assistant (under supervision), or nurse practitioner licensed in Michigan must evaluate the patient, document a clinical indication, and issue a written prescription for compounded thymosin beta-4. Telehealth prescribing is permitted in Michigan for established patient-provider relationships under MCL 333.16285, provided the prescriber holds an active Michigan license.

Step 2: Identify a Compliant Compounding Pharmacy

The prescribing clinician or the patient must identify a 503A-licensed compounding pharmacy registered with both the FDA and the Michigan Board of Pharmacy. Given TB-500's unlisted status, the pharmacy's compliance team should be able to explain its legal rationale for compounding the substance. A pharmacy that cannot provide that explanation should not be used.

Key questions to ask the pharmacy:

• Is the API sourced from an FDA-registered manufacturer with a Certificate of Analysis?
• Does the pharmacy hold a current Michigan pharmacy license and USP 797-compliant sterile compounding certification?
• Has the pharmacy received any FDA warning letters related to peptide compounding?

The FDA's Warning Letters database is publicly searchable and should be reviewed before selecting a pharmacy.

Step 3: Understand What You Are Receiving

Legally compounded TB-500 for human use must be accompanied by a patient-specific label, dispensed by the compounding pharmacy directly to the patient or prescribing clinic, and stored under conditions specified by the pharmacy. It cannot be purchased in bulk "research vials" and self-administered. That pathway constitutes use of an unapproved drug, which carries legal and safety risk.

Research Chemical Sales and Why They Are Not a Legal Option for Humans

A large online market sells TB-500 in lyophilized vials labeled "for research use only, not for human use." These products are sold without prescription and without any FDA oversight of sterility, potency, or purity. Under FDA's interpretation, the "research use only" label does not create a legal safe harbor if the product is marketed with implied human-use claims (such as dosing guidance in milligrams per kilogram body weight).

FDA Enforcement Actions Against Research Chemical Peptides

FDA has issued multiple warning letters to online peptide vendors. In 2023 and 2024, FDA warned several companies marketing BPC-157, CJC-1295, and related peptides, noting that their products were unapproved new drugs. While TB-500 was not named in every letter, the regulatory rationale applies equally. The FDA's 2024 import alert IA-66-41 covers unapproved drug products and has been used to seize peptide shipments at U.S. Ports of entry.

Purchasing TB-500 from a research chemical vendor does not violate the CSA because it is not scheduled. However, it may violate 21 U.S.C. § 331(a) (introduction of an unapproved new drug into interstate commerce) if the purchaser can be shown to have administered it therapeutically. For practical purposes, individual buyers are rarely prosecuted, but the vendor and any health professional who directed the purchase face meaningful enforcement risk.

WADA Prohibition and Athletic Implications

For any Michigan athlete subject to anti-doping rules, TB-500 is unambiguously prohibited. WADA's Prohibited List classifies thymosin beta-4 and its synthetic fragments under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which is prohibited both in-competition and out-of-competition. The 2024 WADA Prohibited List explicitly names "TB-500" and "thymosin beta-4" as examples of prohibited S2 substances.

NCAA, USADA, and Michigan High School Athletic Association (MHSAA) drug-testing programs all incorporate the WADA framework. A positive test for TB-500 metabolites carries the same sanction as other prohibited peptide hormones: typically a two-year suspension for a first offense under the World Anti-Doping Code Article 10.2.

Safety Considerations a Michigan Prescriber Must Address

Even if the legal pathway is navigated correctly, TB-500 presents clinical uncertainties that any prescribing Michigan physician must disclose to the patient.

Absence of Phase III Human Trial Data

No completed, peer-reviewed Phase III randomized controlled trial has evaluated TB-500 in humans as of July 2025. The evidence base consists of animal studies and small, uncontrolled human case reports. A 2017 review in Pharmacology and Therapeutics (PMID 28111189) summarized preclinical wound-healing data favorably but explicitly noted that "clinical translation remains unproven." Prescribing outside an IRB-approved protocol means the patient is effectively an N-of-1 experiment.

Sterility and Purity Risk

Compounded sterile preparations carry infection risk if USP 797 standards are not met. The FDA's 2012 meningitis outbreak investigation linked 64 deaths to a non-compliant compounding facility, underscoring that sterility standards exist for a reason. Any Michigan physician directing a patient to a compounding pharmacy should verify that facility's most recent inspection record through the FDA's Establishment Inspection Report database.

Informed Consent Language

The American Society of Health-System Pharmacists (ASHP) recommends that prescribers using compounded preparations without approved equivalents document informed consent that includes: (1) the absence of FDA approval, (2) the compounded nature of the product, (3) the known and unknown risks, and (4) available alternatives. Michigan's informed consent statute (MCL 333.17013) requires disclosure of material risks in language the patient understands.

What a Legitimate TB-500 Prescription in Michigan Looks Like

A valid Michigan prescription for compounded thymosin beta-4 must contain:

• Patient full name and date of birth
• Prescriber's name, DEA number (even though not scheduled, pharmacies require it for controlled-substance verification infrastructure), and Michigan license number
• Drug name: "Thymosin Beta-4 (TB-500 fragment), sterile compounded" with strength in mg/mL
• Quantity, route (subcutaneous injection), and frequency
• Date of issue and number of refills (zero refills is standard for first dispensing of a gray-area compound)
• Prescriber's signature and direct contact number for pharmacy verification

Prescriptions transmitted via fax or electronic prescribing system must comply with Michigan's e-prescribing requirements under MCL 333.17754a.

Frequently Asked Questions